arrow
A

Aimeé M. Crago

Memorial Sloan Kettering Cancer Center
H指数:37
被引数:6,716

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience

侵袭性血管肌纤维母细胞瘤的自然病史和治疗结果:单一机构经验

2026-09-010
PRE
An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)

一项开放标签的IIa期研究,评估肿瘤内注射tigilanol tiglate(TT)在晚期和/或转移性软组织肉瘤(STS)中的初步疗效。

2024-09-010
PRE
Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naive, advanced gastrointestinal stromal tumor (GIST)

循环肿瘤DNA(ctDNA)作为分子生物标志物在伊马替尼联合比尼替尼治疗初治、晚期胃肠道间质瘤(GIST)II期试验中的价值

2024-09-010
PRE
ASO Visual Abstract: Sentinel Lymph Node Biopsy for Extremity and Truncal Soft Tissue Sarcomas-A Systematic Review of the Literature
2022-11-020
PRE
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

软组织和骨肉瘤的临床测序描绘了不同的基因组景观和潜在的治疗靶点

2022-06-15100
OAAI
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
2021-02-01267
OAAI
The association between tumor mutational burden and prognosis is dependent on treatment context
2021-01-04166
OAAI